Quality Management System


Almac Diagnostic Services Craigavon and Durham laboratory sites hold multiple accreditations and laboratory permits in compliance with various regulations as outlined below.

Our Approach

The Almac Quality Management System (QMS) is managed by a multi-disciplinary team including experts in Quality Assurance, Quality Systems, Validation & Regulatory Affairs. Our QMS covers the design, development and manufacture of in vitro diagnostic (IVD) devices, in addition to the quality requirements of the clinical testing laboratories which includes all aspects of the pre-analytical, analytical and post analytical phases of testing to ensure patient safety goals are addressed.

UK Laboratory Site (Craigavon, NI)

Accreditation / Licence / Permit Certificate Number Authorising body 
Clinical Laboratory Improvement Amendments (CLIA)99D2017022Centers for Medicare & Medicaid Services (CMS) via CAP
College of American Pathologists (CAP)7526035CAP
New York Clinical Laboratory Evaluation Program (NY CLEP)8723New York Department of Health
California Clinical Laboratory LicenceCDS00800369California Department of Public Health
Pennsylvania Clinical Laboratory Permit32234Pennsylvania Department of Health
Maryland Clinical Laboratory Permit2398Maryland Department of Health
Rhode Island Clinical Laboratory PermitLCO01008Rhode Island Department of Health
IEC62304:2006/ AMD1:2015A28674UL

US Laboratory Site (Durham, NC)

Accreditation / Licence / Permit Certificate Number Authorising body 
CLIA34D2102308CMS via CAP
NY CLEP9177New York Department of Health
California Clinical Laboratory LicenceCDS00800769California Department of Public Health
Pennsylvania Clinical Laboratory Permit35352Pennsylvania Department of Health
Maryland Clinical Laboratory Permit2984Maryland a Department of Health
Rhode Island Clinical Laboratory PermitLCO01091/LCO01415Rhode Island Department of Health

How our Quality Systems Integrate

Almac Diagnostic Services operate under one unified QMS. The diagram below provides a broad overview of what activities are governed by the relevant regulations and certifications which the QMS complies to.

Product Development

For product development, a feasibility/research and development (R&D) phase is generally instigated at the start of a project. Next, the majority of assays are developed as clinical trial assays (CTAs) intended to be used for subject selection/stratification onto clinical trials or to establish the assays clinical performance characteristics. These assays are subject to development under Design Control which meets ISO13485 and 21 CFR 820.30 and ensures they meet the requirements of their intended use. Clinical Trial Assays in addition utilised to analyse samples from trials are analytically validated so that they are fit for purpose for their trial use and meet GCLP principles, and therefore GCP requirements.


In parallel, software developed for the CTA functionality is developed under IEC62304.This ensures that the software is developed under a Quality management system incorporating risk management activities ensuring the extent and scope of the development and testing is based on the based on potential for hazard(s) that could cause injury to the user or patient.

In Vitro Diagnostics (IVD)

Similarly, IVD’s which have been designed and developed under ISO13485/21 CFR 820 and have undergone both analytical and clinical performance evaluation and regulatory approval are manufactured to these standards. They are then subsequently released for commercial use either as a kit to other laboratories or as a functional tested batch of reagents for use on specifically approved instruments in the Almac Diagnostic Services clinical laboratory. 

CLIA Regulations

Assays listed on the UKAS scope of accreditation for UK clinical laboratory work are governed by ISO15189.  All US and UK clinical laboratory assays, where required by regulation, are governed by CLIA and are accredited by the College of American Pathologists (CAP).

Quality System Compliance

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies